Anti-HIV activity of some synthetic lignanolides and intermediates

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 17, 2004, Pages 4483-4486

  Sancho, Rocío ^a   Medarde, Manuel ^b   Sánchez Palomino, Sonsoles ^c   Madrigal, Blanca M ^b   Alcamí, José ^c   Muñoz, Eduardo ^a   San Feliciano, Arturo ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anti HIV 1; HIV 1 promoter activation; HIV 1 Tat protein; Synthetic lignanolides; Transcription factor NF B

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGNAN DERIVATIVE; MACROLIDE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PROMOTER REGION; VIRUS RECOMBINATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; HELA CELLS; HIV-1; HUMANS; LIGNANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 3843105997     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.06.047     Document Type: Article

References (27)

1. Stevenson M. Nat. Med. 9:2003;853
2. Moore J.P., Stevenson M. Nat. Rev. Mol. Cell Biol. 1:2000;40
3. Yeni P.G., Hammer S.M., Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schechter M., Schooley R.T., Thompson M.A., Vella S., Volberding P.A. JAMA. 288:2002;222
4. Stevenson M. Nat. Med. 9:2003;163
5. Karin M., Yamamoto Y., Wang Q.M. Nat. Rev. Drug Discov. 3:2004;17
6. Pande V., Ramos M.J. Curr. Med. Chem. 10:2003;1603
7. Rohr O., Marban C., Aunis D., Schaeffer E. J. Leukoc Biol. 74:2003;736
8. Rabson A.B., Lin H.C. Adv. Pharmacol. 48:2000;161
9. Alcami J., Lain de Lera T., Folgueira L., Pedraza M.A., Jacque J.M., Bachelerie F., Noriega A.R., Hay R.T., Harrich D., Gaynor R.B., et al. Embo J. 14:1995;1552
10. TAR is a cis-activating stem-loop RNA structure called transactivating response element present in the HIV-1 LTR promoter. Through interaction with TAR, Tat recruits a host cell protein kinase complex, p-TEFb (CDK9 and CycT) that binds to the loop region of TAR. As a consequence of the p-TEFb recruitment to the HIV-1 promoter complex, the C-terminal domain (CTD) of the RNA polymerase II is phosphorylated increasing the efficiency of transcription elongation
11. Ptak R.G. Expert Opin Investig. Drugs. 11:2002;1099
12. Demarchi F., Gutierrez M.I., Giacca M. J. Virol. 73:1999;7080
13. Sancho R., Calzado M.A., Di Marzo V., Appendino G., Munoz E. Mol. Pharmacol. 63:2003;429
14. Sancho, R.; Marquez, N.; Gómez-Gonzalo, M.; Calzado, M. A.; Bettoni, G.; Coiras, M.; Alcamí, J.; Lopez-Cabrera, M.; Appendino, G.; Muñoz, E. J. Biol. Chem. 2004, in press. doi:10.1074/jbc.M401993200
15. 2, 1 mM DTT, 1% Triton X-100, and 7% glycerol and luciferase activity was measured using an Autolumat LB 953 (EG & G Berthold, USA) following the instructions of the luciferase assay kit (Promega, Madison, WI, USA). TNFα induces an average of 15-20 fold induction of the luciferase activity compared to nonstimulated cells and this represent the index of transactivation that is represented in our experiment as the maximum levels of TNFα-induced NF- κ B activation (100%).
16. 5 cells/mL), seeded the day before the assay, were treated either with the CDK9 inhibitor DRB, as a positive control, or with three doses of the compounds tested. After 12 h, the cells were washed twice with PBS and the luciferase activity measured as indicated for 5.1 cells
17. Marquez N., Sancho R., Macho A., Calzado M.A., Fiebich B.L., Muñoz E. J. Pharmacol. Exp. Ther. 308:2004;993
18. 5 cells/mL) were seeded the day before the assay, and then stimulated with doxycycline (1 μg/mL) in the presence or absence of the compounds for 6 h. Then, the cells were washed twice in PBS, lysed and the luciferase activity measured as described
19. García et al., in preparation
20. Jassim S.A., Naji M.A. J. Appl. Microbiol. 95:2003;412
21. Damayanthi Y., Lown J.W. Curr. Med. Chem. 5:1998;205
22. Madrigal B., Puebla P., Ramos A., Pelaez R., Gravalos D., Caballero E., Medarde M. Bioorg. Med. Chem. 10:2002;303
23. Madrigal B., Puebla P., Pelaez R., Caballero E., Medarde M. J. Org. Chem. 68:2003;854
24. 6 cells/mL were treated with the compounds for 24 h or 48 h at 37°C. Then, collected, resuspended in PBS and analysed by flow cytometry after Propidium Iodide staining to determine the cell death percentage. All the results, showed as % of cell death or CC50 values, were calculated by GraphPad software
25. 50 values, calculated by GraphPad software
26. Karn J. J. Mol. Biol. 293:1999;235
27. Furia B., Deng L., Wu K., Baylor S., Kehn K., Li H., Donnely R., Coleman T., Kashanchi F. J. Biol. Chem. 277:2001;4973